CO2023005753A2 - Cápsulas de gelatina blanda de liberación modificada - Google Patents

Cápsulas de gelatina blanda de liberación modificada

Info

Publication number
CO2023005753A2
CO2023005753A2 CONC2023/0005753A CO2023005753A CO2023005753A2 CO 2023005753 A2 CO2023005753 A2 CO 2023005753A2 CO 2023005753 A CO2023005753 A CO 2023005753A CO 2023005753 A2 CO2023005753 A2 CO 2023005753A2
Authority
CO
Colombia
Prior art keywords
soft gelatin
gelatin capsules
dependent
modified release
controlled release
Prior art date
Application number
CONC2023/0005753A
Other languages
English (en)
Spanish (es)
Inventor
Qi Fang
Karunakar Sukuru
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of CO2023005753A2 publication Critical patent/CO2023005753A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2023/0005753A 2020-10-16 2023-05-05 Cápsulas de gelatina blanda de liberación modificada CO2023005753A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063092762P 2020-10-16 2020-10-16
PCT/US2021/071900 WO2022082222A1 (en) 2020-10-16 2021-10-15 Modified release softgel capsules

Publications (1)

Publication Number Publication Date
CO2023005753A2 true CO2023005753A2 (es) 2023-05-29

Family

ID=81208677

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005753A CO2023005753A2 (es) 2020-10-16 2023-05-05 Cápsulas de gelatina blanda de liberación modificada

Country Status (14)

Country Link
US (1) US20230390210A1 (https=)
EP (1) EP4228597A4 (https=)
JP (1) JP2023547062A (https=)
KR (1) KR20230088388A (https=)
CN (1) CN116322655A (https=)
AR (1) AR123805A1 (https=)
AU (1) AU2021362248A1 (https=)
BR (1) BR112023006154A2 (https=)
CA (1) CA3194160A1 (https=)
CO (1) CO2023005753A2 (https=)
IL (1) IL301715A (https=)
MX (1) MX2023004418A (https=)
TW (1) TW202228656A (https=)
WO (1) WO2022082222A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135085A1 (ja) * 2023-12-22 2025-06-26 花王株式会社 カプセル剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
KR20100047349A (ko) * 2001-11-22 2010-05-07 모리시타 진탄 가부시키가이샤 비젤라틴계 캡슐 피막 조성물 및 이를 이용한 캡슐
KR100575199B1 (ko) * 2003-01-24 2006-05-02 알앤피코리아주식회사 연질 캡슐의 블루밍 방지를 위한 가소제 조성물 및 이를함유한 피막
IT1401313B1 (it) * 2010-08-05 2013-07-18 Perfetti Van Melle Spa Caramelle gelatinose con ripieno fluido e metodo di ottenimento
US20120301546A1 (en) * 2011-05-26 2012-11-29 Hassan Emadeldin M Acid-resistant soft gel compositions
GB201304662D0 (en) * 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20150366814A1 (en) * 2014-06-23 2015-12-24 Banner Life Sciences Llc All-natural enteric soft capsules comprising active ingredients
US20170119680A1 (en) * 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
US20210353574A1 (en) * 2018-10-16 2021-11-18 Bayer Healthcare Llc Softgels with solid or gel-like polymeric fill matrix
MX2022005050A (es) * 2019-10-28 2022-07-04 Scherer Technologies Llc R P Cápsulas de gelatina blanda de liberación retardada en entorno de ph más alto.

Also Published As

Publication number Publication date
EP4228597A4 (en) 2024-10-02
AU2021362248A1 (en) 2023-06-01
MX2023004418A (es) 2023-05-04
TW202228656A (zh) 2022-08-01
US20230390210A1 (en) 2023-12-07
CN116322655A (zh) 2023-06-23
KR20230088388A (ko) 2023-06-19
CA3194160A1 (en) 2022-04-21
AR123805A1 (es) 2023-01-11
WO2022082222A1 (en) 2022-04-21
JP2023547062A (ja) 2023-11-09
BR112023006154A2 (pt) 2023-05-09
IL301715A (en) 2023-05-01
AU2021362248A9 (en) 2024-05-02
EP4228597A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
DOP2012000217A (es) Pastillas de gelatina blanda con nicotina
CL2007002000A1 (es) Preparacion farmaceutica para la administracion oral con liberacion controlada de ingrediente activo en el intestino delgado que comprende portadores inertes, ingredientes activo, una capa interna compuesta de 2 capas de difusion para controlar la liberacion y una capa gastrorresistente; metodo de preparacion.
MX2009004439A (es) Composicion de ibuprofeno.
UY30905A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos
MX2013009773A (es) Vehiculo masticable para absorcion bucal.
CR11625A (es) Formulacion de capsula
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CR11630A (es) Sistema de administracion de drogas con efecto estabilizante
MX384337B (es) Composiciones farmacéuticas liofilizadas para suministro vaginal.
CA3010829A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
CO2023005753A2 (es) Cápsulas de gelatina blanda de liberación modificada
MX2019015733A (es) Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.
CO6321223A2 (es) Formulacion farmaceutica solida que contiene ciclostazol
CO2022019321A2 (es) Cápsulas de gel de liberación retardada
MX2019004938A (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
AR046146A1 (es) Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso
WO2016205397A3 (en) Target-specific delivery of therapeutic agents
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
MX2021002459A (es) Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata.
MD4877B1 (ro) Compoziţie farmaceutică şi comprimat oral de S-adenozilmetionină cu eliberare întârziată
ES2572180T3 (es) Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada
JOP20210135A1 (ar) صيغة توصيل عقار قولوني
MX2020006886A (es) Sistema para suministro de medicamento.